NDC 69097-537-31 Testosterone Cypionate

Testosterone Cypionate

NDC Package Code 69097-537-31

The NDC Code 69097-537-31 is assigned to a package of 1 ml in 1 vial, glass of Testosterone Cypionate, a human prescription drug labeled by Cipla Usa Inc.. The product's dosage form is injection and is administered via intramuscular form.

Field Name	Field Value
NDC Code	69097-537-31
Package Description	1 mL in 1 VIAL, GLASS
Proprietary Name	Testosterone Cypionate What is the Proprietary Name? The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
Non-Proprietary Name	Testosterone Cypionate What is the Non-Proprietary Name? The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
11-Digit NDC Billing Format	69097053731 NDC Format for Billing For insurance billing purposes the Centers for Medicare & Medicaid Services (CMS) created an 11 digit NDC derivative identifier. If the NDC Package code is less than 11 digits the code must be padded with leading zeros. The leading zeros must be added to the appropriate segment to create a 5-4-2 configuration.
Billing Unit	ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Product Type	Human Prescription Drug What kind of product is this? Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
Labeler Name	Cipla Usa Inc.
Dosage Form	Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route(s)	Intramuscular - Administration within a muscle.
Active Ingredient(s)	TESTOSTERONE CYPIONATE 200 mg/mL
Pharmacological Class(es)	Androgen - [EPC] (Established Pharmacologic Class) Androgen Receptor Agonists - [MoA] (Mechanism of Action) Androstanes - [CS]
DEA Schedule	Schedule III (CIII) Substances What is the Drug Enforcement Administration (DEA) CIII Schedule? The controlled substances in the CIII schedule have an abuse potential and dependence liability less than those in schedules CI and CII, and have an accepted medical use in the United States. Schedule CIII controlled substances include preparations containing limited quantities of certain narcotic drugs, and other nonnarcotic drugs such as: derivatives of barbituric acid, except those that are listed in another schedule, glutethimide (Doriden), methyprylon (Noludar), nalorphine, benzphetamine, chlorphentermine, clortermine, and phendimetrazine.
Sample Package	No Sample Package? This field Indicates whether this package is a sample packaging or not.
Marketing Category	ANDA - A product marketed under an approved Abbreviated New Drug Application. What is the Marketing Category? Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
FDA Application Number	ANDA210362 What is the FDA Application Number? This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Start Marketing Date	06-22-2018 What is the Start Marketing Date? This is the date that the labeler indicates was the start of its marketing of the drug product.
Listing Expiration Date	12-31-2020 What is the Listing Expiration Date? This is the date when the listing record will expire if not updated or certified by the product labeler.

NDC Code Structure

69097 - Cipla Usa Inc.
- 69097-537 - Testosterone Cypionate
  - 69097-537-31 - 1 mL in 1 VIAL, GLASS

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the disclaimer below.

NDC HCPCS Crosswalk

This crosswalk is intended to help the public understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes.

NDC 69097-537-31 HCPCS crosswalk information with package details and bill units information.

NDC Billing Code	HCPCS Code	HCPCS Code Desc.	Dosage	Package Size	Package Quantity	Billable Units	Billable Units / Pkg
69097053731	J1071	Inj testosterone cypionate	1 MG	1	1	200	200

* Please review the disclaimer below.

Other Product Packages

The following packages are also available for Testosterone Cypionate with product NDC 69097-537.

NDC Package Code	Package Description
69097-537-37	10 mL in 1 VIAL, GLASS

* Please review the disclaimer below.

Previous Code
69097-536

Next Code
69097-539